NASDAQ · ORMP
Healthcare · Biotechnology
$4.62
Up+$0.06 (+1.30%)
Updated Sep 17, 2026, 7:41 PM
SID Score
6.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ORMP closed at $4.62 after 20 trading sessions, down 3.55% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $4.63 | $4.67 | $4.54 | $4.62 | 122.77K |
| Sep 15, 2026 | $4.64 | $4.655 | $4.55 | $4.62 | 145.85K |
| Sep 14, 2026 | $4.64 | $4.76 | $4.64 | $4.67 | 135.1K |
| Sep 11, 2026 | $4.81 | $4.82 | $4.65 | $4.66 | 144.53K |
| Sep 10, 2026 | $4.74 | $4.854 | $4.66 | $4.76 | 131.47K |
| Sep 9, 2026 | $4.94 | $4.94 | $4.70 | $4.78 | 245.69K |
| Sep 8, 2026 | $4.99 | $5.01 | $4.92 | $4.98 | 118.17K |
| Sep 4, 2026 | $4.92 | $5.05 | $4.86 | $5.01 | 226.87K |
| Sep 3, 2026 | $5.11 | $5.11 | $4.81 | $4.93 | 187.97K |
| Sep 2, 2026 | $4.85 | $5.1499 | $4.85 | $5.07 | 188.61K |
| Sep 1, 2026 | $5.00 | $5.15 | $4.8001 | $4.85 | 255.35K |
| Aug 31, 2026 | $5.03 | $5.06 | $4.90 | $5.02 | 242.85K |
| Aug 28, 2026 | $5.14 | $5.15 | $5.01 | $5.03 | 154.13K |
| Aug 27, 2026 | $5.35 | $5.47 | $5.0601 | $5.10 | 276.4K |
| Aug 26, 2026 | $5.31 | $5.43 | $5.12 | $5.34 | 403.56K |
| Aug 25, 2026 | $4.80 | $5.25 | $4.80 | $5.21 | 641.5K |
| Aug 24, 2026 | $4.80 | $4.86 | $4.74 | $4.82 | 90.74K |
| Aug 21, 2026 | $4.81 | $4.88 | $4.75 | $4.81 | 126.13K |
| Aug 20, 2026 | $4.78 | $4.8599 | $4.68 | $4.79 | 177.18K |
| Aug 19, 2026 | $4.83 | $4.94 | $4.70 | $4.79 | 363.17K |
The latest Smart Investors Daily articles mentioning ORMP.
ORMP research
Company profile and research snapshot.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2024 | HC Wainwright & Co. | Neutral | — |
| May 20, 2024 | HC Wainwright & Co. | Neutral | — |
| May 17, 2023 | Canaccord Genuity | Hold | — |
| Jan 17, 2023 | HC Wainwright & Co. | Neutral | — |
| Jan 12, 2023 | Canaccord Genuity | Hold | — |
No generated briefing is available yet.
SeekingAlpha · Sep 11, 2026
Oramed Pharmaceuticals holds as it shifts to strategic investments; strong returns from Alpha Tau, Lifeward & Scilex, but risks loom. Click for an ORMP update.
Yahoo · Sep 8, 2026
HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced that an updated investor presentation is available on the Company's investor relations website. The presentation provides an overview of Lifeward's strategy to scale its established rehabilitation platform, levera
Yahoo · Jun 25, 2026
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. The letter highlights the Company's addition to the Russell 2000 and Russell 3000 indexes, the substantial repayment of its Scilex loan, and a strengthened balance sheet of approximately $270 million in total cash and assets, as of March 31, 2026 (unaudited).
Benzinga · Jun 25, 2026
Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday's regular session. The company's market cap stands at $59.4 million. As per the press release, Q1 earnings came out
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ORMP.
